"10.1371_journal.pone.0028947","plos one","2011-12-12T00:00:00Z","Michael T Dellinger; Rolf A Brekken","Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America; Hamon Center for Therapeutic Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America","Conceived and designed the experiments: MTD RAB. Performed the experiments: MTD. Analyzed the data: MTD RAB. Wrote the paper: MTD RAB.","R. A. Brekken is a consultant for, has equity interest in, and is a recipient of a sponsored grant from Affitech AS. R. A. Brekken is also an author of a patent on technology that was used to develop the antibody r84 by Affitech AS and Peregrine Pharmaceuticals Inc. Affitech AS and Peregrine Pharmaceuticals Inc. did not participate in the planning, execution, or interpretation of experiments. The authors affirm that they will adhere to all of the PLoS ONE policies on sharing data and materials..","2011","12","Michael T Dellinger","MTD",2,TRUE,2,1,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
